(Q44135492)

30 November 2017

title

Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases (English)

1 reference

30 November 2017

0 references

antimicrobial resistance

1 reference

David J Serisier

1

1 reference

30 November 2017

publication date

29 March 2013

1 reference

The Lancet. Respiratory medicine

30 November 2017

published in

1 reference

30 November 2017

volume

1

1 reference

30 November 2017

issue

3

1 reference

30 November 2017

page(s)

262-274

1 reference

Mechanisms of action and clinical application of macrolides as immunomodulatory medications

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Azithromycin for prevention of exacerbations of COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Society's failure to protect a precious resource: antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Urgently needed: new antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Antimicrobial susceptibility of Streptococcus pneumoniae in eight European countries from 2001 to 2003.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Evolution of macrolide resistance in Streptococcus pneumoniae clinical isolates in the prevaccine era

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Increase in pneumococcus macrolide resistance, United States

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Epidemiology and characteristics of antimicrobial resistance in China

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Macrolide-resistant Mycoplasma pneumoniae: characteristics of isolates and clinical aspects of community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Molecular mechanisms of macrolide resistance in clinical isolates of Mycoplasma pneumoniae from China

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Long-term macrolide treatment of chronic inflammatory airway diseases: risks, benefits and future developments.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Chronic macrolide therapy in inflammatory airways diseases

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Antibiotic prevention of acute exacerbations of COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

The use of erythromycin as a gastrointestinal prokinetic agent in adult critical care: benefits versus risks

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Macrolide and ketolide resistance with Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Macrolide treatment failure in streptococcal pharyngitis resulting in acute rheumatic fever.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

A Phase I Determination of Azithromycin in Plasma during a 6-Week Period in Normal Volunteers after a Standard Dose of 500mg Once Daily for 3 Days

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Antimicrobial use and antimicrobial resistance: a population perspective

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Mechanisms by which antibiotics promote dissemination of resistant pneumococci in human populations

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Measuring and interpreting associations between antibiotic use and penicillin resistance in Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Resistance to macrolides and related antibiotics in Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Unconstrained bacterial promiscuity: the Tn916-Tn1545 family of conjugative transposons.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Distribution and antibacterial susceptibility of macrolide resistance genotypes in Streptococcus pneumoniae: PROTEKT Year 5 (2003-2004).

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

The decline of pneumococcal resistance after cessation of mass antibiotic distributions for trachoma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster-randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Effects of amoxicillin/clavulanate or azithromycin on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae in children with acute otitis media

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

The association between antibiotic use in the community and nasopharyngeal carriage of antibiotic-resistant Streptococcus pneumoniae in Bedouin children

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Community prescribing and resistant Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Outpatient antibiotic prescribing and nonsusceptible Streptococcus pneumoniae in the United States, 1996-2003.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Macrolide resistance among invasive Streptococcus pneumoniae isolates

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Emergence of invasive erythromycin-resistant Streptococcus pneumoniae strains in Portugal: contribution and phylogenetic relatedness of serotype 14.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Trends in resistance to penicillin and erythromycin of invasive pneumococci in Portugal

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Importance of local variations in antibiotic consumption and geographical differences of erythromycin and penicillin resistance in Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Streptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolide and beta-lactam consumption in Spain (1979-1997).

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Do antimicrobials increase the carriage rate of penicillin resistant pneumococci in children? Cross sectional prevalence study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Macrolide-resistant Streptococcus pneumoniae and use of antimicrobial agents

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Macrolide and azithromycin use are linked to increased macrolide resistance in Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Antimicrobial use and colonization with erythromycin-resistant Streptococcus pneumoniae in Greece during the first 2 years of life

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Annual macrolide prescription rates and the emergence of macrolide resistance among Streptococcus pneumoniae in Canada from 1995 to 2005.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Predicting antimicrobial resistance in invasive pneumococcal infections

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Emergence of macrolide and penicillin resistance among invasive pneumococcal isolates in Germany

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

A prospective study of the impact of community-based azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Dynamics of pneumococcal nasopharyngeal colonization during the first days of antibiotic treatment in pediatric patients.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Outpatient antibiotic use in Europe and association with resistance: a cross-national database study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Impact of azithromycin on oropharyngeal carriage of group A Streptococcus and nasopharyngeal carriage of macrolide-resistant Streptococcus pneumoniae.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Macrolide prescriptions and erythromycin resistance of Streptococcus pyogenes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Erythromycin Resistance in Streptococcus pyogenes and Macrolide Consumption in a Central Italian Region

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Streptococcus pyogenes resistance to erythromycin in relation to macrolide consumption in Spain (1986-1997).

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Effect of macrolide consumption on erythromycin resistance in Streptococcus pyogenes in Finland in 1997-2001.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Emergence and persistence of macrolide resistance in oropharyngeal flora and elimination of nasal carriage of Staphylococcus aureus after therapy with slow-release clarithromycin: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Influence of macrolide antibiotics on promotion of resistance in the oral flora of children

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Influence of azithromycin and clarithromycin on macrolide susceptibility of viridans streptococci from the oral cavity of healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Results of the Alexander Project: a continuing, multicenter study of the antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979-1987. The Pneumococcal Surveillance Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007).

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Antibiotic susceptibility of Streptococcus pneumoniae isolates in Portugal. A multicenter study between 1989 and 1993.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

The Viriato study: update on antimicrobial resistance of microbial pathogens responsible for community-acquired respiratory tract infections in Portugal.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

In vitro selection of resistance to four beta-lactams and azithromycin in Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Large dosage amoxicillin/clavulanate, compared with azithromycin, for the treatment of bacterial acute otitis media in children

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Antibiotic consumption and resistance selection in Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Increasing antibiotic resistance among otitis media pathogens and their susceptibility to oral agents based on pharmacodynamic parameters

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Antimicrobial drugs and community-acquired methicillin-resistant Staphylococcus aureus, United Kingdom.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Antibiotic selection of multiply resistant pneumococci.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Distribution of erythromycin esterase and rRNA methylase genes in members of the family Enterobacteriaceae highly resistant to erythromycin

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Evidence of extensive interspecies transfer of integron-mediated antimicrobial resistance genes among multidrug-resistant Enterobacteriaceae in a clinical setting

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Evolution and global dissemination of macrolide-resistant group A streptococci

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Failure of Macrolide Antibiotic Treatment in Patients with Bacteremia Due to Erythromycin‐Resistant Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Breakthrough pneumococcal bacteraemia in patients treated with clarithromycin or oral beta-lactams

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

A review of clinical failures associated with macrolide-resistant Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Emergence of macrolide resistance during treatment of pneumococcal pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

A trial of clarithromycin for the treatment of suboptimally controlled asthma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Trial of roxithromycin in subjects with asthma and serological evidence of infection with Chlamydia pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

The effect of telithromycin in acute exacerbations of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Antibiotic resistance in sputum isolates of Streptococcus pneumoniae in chronic obstructive pulmonary disease is related to antibiotic exposure.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Long-term, low-dose erythromycin in bronchiectasis subjects with frequent infective exacerbations.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

The rise and fall of antimicrobial resistance

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

EM703, a new derivative of erythromycin, inhibits transforming growth factor-beta signaling in human lung fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

Development of non-antibiotic macrolide that corrects inflammation-driven immune dysfunction in models of inflammatory bowel diseases and arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2813%2970038-9

7 January 2021

10.1016/S2213-2600(13)70038-9

Identifiers

DOI

1 reference

release_aphf4osyq5devih366rgfqhqvm

30 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/aphf4osyq5devih366rgfqhqvm

24 November 2022

mapped directly with Wikidata item

1 reference